Cognition Therapeutics
CGTX
31 hedge funds and large institutions have $9.7M invested in Cognition Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
11% more funds holding
Funds holding: 28 → 31 (+3)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
0.53% less ownership
Funds ownership: 22.96% → 22.43% (-0.53%)
13% less capital inflows, than outflows
Capital inflows: $1.35M | Capital outflows: $1.56M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$688K |
| 2 |
Carlson Capital
Dallas,
Texas
|
+$208K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$136K |
| 4 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$104K |
| 5 |
Two Sigma Investments
New York
|
+$50.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nantahala Capital Management
New Canaan,
Connecticut
|
-$407K |
| 2 |
Prosight Management
Dallas,
Texas
|
-$254K |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$234K |
| 4 |
Voss Capital
Houston,
Texas
|
-$188K |
| 5 |
Perigon Wealth Management
San Francisco,
California
|
-$179K |
CGTX Hedge Fund Activity: Q3 2022 in Review
31 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q3 2022, worth a combined $9.7M — down 15% from $11.4M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CGTX positions and 4 closed out — a net gain of 3 holders — while 7 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $688K. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $407K sold.
- 31 institutional investors held Cognition Therapeutics (CGTX) as of Q3 2022, up from 28 in Q2 2022.
- Funds reported $9.7M of Cognition Therapeutics stock for Q3 2022, down 15% quarter-over-quarter.
- 7 funds opened new Cognition Therapeutics positions in Q3 2022 and 4 closed out, a net change of +3 holders.
- The largest Cognition Therapeutics buyer in Q3 2022 was Vanguard Group, an estimated $688K added.
- The largest Cognition Therapeutics seller in Q3 2022 was Nantahala Capital Management, an estimated $407K sold.
Based on aggregated 13F filings for Q3 2022.